BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Cerilliant
Chubb
Queensland Health
Fish and Richardson
Moodys
Covington
Argus Health
AstraZeneca

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,231,885

« Back to Dashboard

Which drugs does patent 8,231,885 protect, and when does it expire?

Patent 8,231,885 protects MIRVASO and is included in one NDA.

This patent has sixty-three patent family members in twenty-four countries.
Summary for Patent: 8,231,885
Title:Compounds, formulations, and methods for ameliorating telangiectasis
Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:12/544,663
Patent Claim Types:
see list of patent claims
Composition; Delivery; Formulation;

Drugs Protected by US Patent 8,231,885

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,231,885

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,513,247 Methods and compositions for safe and effective treatment of erythema ➤ Subscribe
7,439,241 Compounds, formulations, and methods for treating or preventing rosacea ➤ Subscribe
8,586,586 Methods and compositions for treating or preventing erythema ➤ Subscribe
7,838,563 Compounds, formulations, and methods for ameliorating telangiectasias ➤ Subscribe
8,513,249 Methods and compositions for safe and effective treatment of erythema ➤ Subscribe
8,426,410 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,410,102 Methods and compositions for treating or preventing erythema ➤ Subscribe
8,993,571 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,557,817 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
8,859,551 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,231,885

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2388007 ➤ Subscribe
Slovenia 1761266 ➤ Subscribe
Slovenia 1631293 ➤ Subscribe
Russian Federation 2519676 ➤ Subscribe
Russian Federation 2012145616 ➤ Subscribe
Portugal 2552449 ➤ Subscribe
Portugal 2388007 ➤ Subscribe
Portugal 1761266 ➤ Subscribe
Portugal 1631293 ➤ Subscribe
Poland 2552449 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Chubb
McKinsey
US Department of Justice
Merck
Dow
Fuji
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot